172 related articles for article (PubMed ID: 7459898)
1. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ
Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898
[TBL] [Abstract][Full Text] [Related]
2. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
3. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
4. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
6. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
Rudolf Z; Plesnicar S
Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
[TBL] [Abstract][Full Text] [Related]
8. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
14. cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.
Karakousis CP; Getaz EP; Bjornsson S; Henderson ES; Irequi M; Martinez L; Ospina J; Cavins J; Preisler H; Holyoke E; Holtermann O
Cancer Treat Rep; 1979; 63(11-12):2009-10. PubMed ID: 393386
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
Chauvergne J; Bui NB; Cappelaere P; Gary-Bobo J; Guerrin J; Armand JP; Durand M
Sem Hop; 1982 Dec; 58(46):2697-701. PubMed ID: 6297068
[TBL] [Abstract][Full Text] [Related]
16. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
17. [A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma].
Domyo M; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Aiba K; Nagata T; Miyamoto H
Gan To Kagaku Ryoho; 1982 May; 9(5):874-9. PubMed ID: 6964041
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
Samson MK; Baker LH; Cummings G; Talley RW; McDonald B; Bhathena DB
Cancer Treat Rep; 1982 Feb; 66(2):371-3. PubMed ID: 6459845
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
20. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]